Translational lung cancer research · 2026
Targeted dual-responsive nanocapsules for synergistic cisplatin and paclitaxel prodrug delivery in the treatment of lung cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xinyu, Qin Dan, Yao Chunyu, Ji Xiang, Li Chuankui, Tao Tao, Chen Xinyu, Li Qicai, Yang Yifan, Li Lixiang, Wang Zuyi, Zhang Xiaonan, Wang Guowen
Аннотация
BACKGROUND: The clinical application of traditional chemotherapy for treating patients with lung cancer is restricted by its poor targeting efficacy and severe systemic toxicity. In this study, we developed an acid-sensitive lipid-polymer nanocapsule (PTX/Pt@RGD) for the co-delivery of a redox-sensitive paclitaxel (PTX) prodrug and cisplatin (Pt), which can facilitate both tumor microenvironment-responsive drug release and active targeting.
METHODS: The physicochemical properties of the nanocapsules were characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The drug-loading efficiency and release profile were analyzed via high-performance liquid chromatography (HPLC). In vitro antitumor activity was evaluated with Cell Counting Kit-8 assay, Annexin V/propidium iodide (PI) double staining, and Transwell assay. The underlying mechanisms were explored via reactive oxygen species (ROS) detection to assess oxidative stress levels, JC-1 mitochondrial membrane potential assay to evaluate mitochondrial dysfunction, γ-H2AX immunofluorescence to quantify DNA double-strand breaks, and Western blot analysis to determine the expression of apoptosis-related proteins. Tumor-bearing mouse models were established to assess the in vivo targeting efficacy, therapeutic effect, and biosafety of PTX/Pt@RGD.
RESULTS: PTX/Pt@RGD exhibited a regular spherical morphology with a particle size of 99.4 nm, a drug-loading efficiency of 2.60%, an encapsulation efficiency (EE) of 44.68%, and the ability for pH/redox dual-responsive drug release. In vitro, PTX/Pt@RGD induced apoptosis by promoting ROS generation, reducing mitochondrial membrane potential, causing DNA damage, and activating apoptotic proteins, resulting in a total apoptosis rate of 84.2% in the group treated with PTX/Pt@RGD. In vivo, arginine-glycine-aspartic acid (RGD) modification enhanced tumor-specific accumulation, effectively suppressing tumor growth and angiogenesis, and demonstrated a favorable safety profile.
CONCLUSIONS: PTX/Pt@RGD integrates active targeting with pH/redox dual-responsive release, achieving a high tumor-to-background ratio and efficacy comparable to that of the free PTX/cisplatin combination, together with reduced systemic toxicity and a favorable in vivo safety profile. Although the in vivo therapeutic benefit of RGD-mediated targeting warrants further investigation, our findings support the proactive evaluation of this combinatorial nanoplatform for lung cancer combination chemotherapy.
METHODS: The physicochemical properties of the nanocapsules were characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The drug-loading efficiency and release profile were analyzed via high-performance liquid chromatography (HPLC). In vitro antitumor activity was evaluated with Cell Counting Kit-8 assay, Annexin V/propidium iodide (PI) double staining, and Transwell assay. The underlying mechanisms were explored via reactive oxygen species (ROS) detection to assess oxidative stress levels, JC-1 mitochondrial membrane potential assay to evaluate mitochondrial dysfunction, γ-H2AX immunofluorescence to quantify DNA double-strand breaks, and Western blot analysis to determine the expression of apoptosis-related proteins. Tumor-bearing mouse models were established to assess the in vivo targeting efficacy, therapeutic effect, and biosafety of PTX/Pt@RGD.
RESULTS: PTX/Pt@RGD exhibited a regular spherical morphology with a particle size of 99.4 nm, a drug-loading efficiency of 2.60%, an encapsulation efficiency (EE) of 44.68%, and the ability for pH/redox dual-responsive drug release. In vitro, PTX/Pt@RGD induced apoptosis by promoting ROS generation, reducing mitochondrial membrane potential, causing DNA damage, and activating apoptotic proteins, resulting in a total apoptosis rate of 84.2% in the group treated with PTX/Pt@RGD. In vivo, arginine-glycine-aspartic acid (RGD) modification enhanced tumor-specific accumulation, effectively suppressing tumor growth and angiogenesis, and demonstrated a favorable safety profile.
CONCLUSIONS: PTX/Pt@RGD integrates active targeting with pH/redox dual-responsive release, achieving a high tumor-to-background ratio and efficacy comparable to that of the free PTX/cisplatin combination, together with reduced systemic toxicity and a favorable in vivo safety profile. Although the in vivo therapeutic benefit of RGD-mediated targeting warrants further investigation, our findings support the proactive evaluation of this combinatorial nanoplatform for lung cancer combination chemotherapy.